omniture
药明生物 WuXi Biologics

Latest News

WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing

WUXI, China, June 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...

2019-06-21 08:39 1397

WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract

SHANGHAI, May 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open...

2019-05-21 07:30 1280

WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu

CHENGDU, China, May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading globa...

2019-05-16 15:39 995

WuXi Biologics Successfully Completed First FDA Routine GMP Inspection

SHANGHAI, April 17, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global op...

2019-04-17 09:14 1429

WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

SHANGHAI, April 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global op...

2019-04-16 20:00 492

WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

SHANGHAI and BASEL, Switzerland, April 9, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK...

2019-04-09 08:36 695

WuXi Biologics Wins 2019 CMO Leadership Awards in All Six Core Categories

SHANGHAI and NEW YORK, April 3, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leadi...

2019-04-03 20:06 506

WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC

SHANGHAI and SINGAPORE, March 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock Code: 226...

2019-03-26 08:24 452

WuXi Biologics Receives EMA GMP Certificates

SHANGHAI and WUXI, China, March 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a l...

2019-03-20 08:07 4187

WuXi Biologics Continues to Deliver Record Results

HONG KONG, March 18, 2019 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Gr...

2019-03-18 22:25 677

WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA

- The second product successfully receiving Breakthrough Therapy Designation that WuXi Biologics ...

2019-02-28 09:52 332

ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million

SHANGHAI and SEOUL, Feb. 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading ...

2019-02-26 08:23 510

EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo (TM) at WuXi Biologics

SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ope...

2019-02-19 14:21 276

EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics

SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ope...

2019-02-19 08:21 337

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

SHANGHAI and CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a...

2019-02-12 08:04 361

WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership

* AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Ent...

2018-12-19 20:16 428

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

SHANGHAI, Dec. 13, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biol...

2018-12-13 07:30 422

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

SHANGHAI, Dec. 12, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biol...

2018-12-12 08:08 372

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

SHANGHAI and OXFORD, the United Kingdom, Dec. 11, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a ...

2018-12-11 15:00 353

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

SHANGHAI and OXFORD, the United Kingdom, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a...

2018-12-11 09:47 372
123